Table of Contents Author Guidelines Submit a Manuscript
Sarcoma
Volume 2011 (2011), Article ID 834170, 5 pages
http://dx.doi.org/10.1155/2011/834170
Research Article

Impairment of Methotrexate Transport Is Common in Osteosarcoma Tumor Samples

1Division of Hematology/Oncology, Department of Pediatrics, The Children's Hospital at Montefiore, The Albert Einstein College of Medicine of Yeshiva University, 3415 Bainbridge Avenue, Rosenthal Rm 300, Bronx, NY 10467, USA
2Department of Pediatrics, Memorial Sloan-Kettering Cancer Center New York, NY 10065, USA
3c/o Veterans Administration New York Harbor Healthcare System, Narrows Institute for Biomedical Research Brooklyn, NY 11209, USA
4Charlotte Kimelman Cancer Institute, 9048 Sugar Estate, St. Thomas USVI 00802, British Virgin Islands
5Division of Orthopaedic Surgery, Department of Surgery, Memorial Sloan-Kettering Cancer Center New York, NY 10065, USA

Received 13 September 2010; Accepted 15 November 2010

Academic Editor: Stephen Lessnick

Copyright © 2011 Rebecca Sowers et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. J. Kim, P. N. Chalmers, and C. D. Morris, “Pediatric osteogenic sarcoma,” Current Opinion in Pediatrics, vol. 22, no. 1, pp. 61–66, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. N. Delepine, G. Delepine, H. Cornille, F. Brion, P. Arnaud, and J. C. Desbois, “Dose escalation with pharmacokinetics monitoring in methotrexate chemotherapy of osteosarcoma,” Anticancer Research, vol. 15, no. 2, pp. 489–494, 1995. View at Google Scholar · View at Scopus
  3. N. Graf, K. Winkler, M. Betlemovic, N. Fuchs, and U. Bode, “Methotrexate pharmacokinetics and prognosis in osteosarcoma,” Journal of Clinical Oncology, vol. 12, no. 7, pp. 1443–1451, 1994. View at Google Scholar · View at Scopus
  4. J. R. Bertino, “Ode to methotrexate,” Journal of Clinical Oncology, vol. 11, no. 1, pp. 5–14, 1993. View at Google Scholar · View at Scopus
  5. F. M. Sirotnak, “Obligate genetic expression in tumor cells of a fetal membrane property mediating 'folate' transport: biological significance and implications for improved therapy of human cancer,” Cancer Research, vol. 45, no. 9, pp. 3992–4000, 1985. View at Google Scholar · View at Scopus
  6. B. Ching Ding, T. L. Witt, B. Hukku, H. Heng, L. Zhang, and L. H. Matherly, “Association of deletions and translocation of the reduced folate carrier gene with profound loss of gene expression in methotrexate-resistant K562 human erythroleukemia cells,” Biochemical Pharmacology, vol. 61, no. 6, pp. 665–675, 2001. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Gorlick, E. Goker, T. Trippett, M. Waltham, D. Banerjee, and J. R. Bertino, “Intrinsic and acquired resistance to methotrexate in acute leukemia,” New England Journal of Medicine, vol. 335, no. 14, pp. 1041–1048, 1996. View at Publisher · View at Google Scholar · View at Scopus
  8. T. Trippett, S. Schlemmer, Y. Elisseyeff et al., “Defective transport as a mechanism of acquired resistance to methotrexate in patients with acute lymphocytic leukemia,” Blood, vol. 80, no. 5, pp. 1158–1162, 1992. View at Google Scholar · View at Scopus
  9. N. Skacel, L. G. Menon, P. J. Mishra et al., “Identification of amino acids required for the functional up-regulation of human dihydrofolate reductase protein in response to antifolate treatment,” Journal of Biological Chemistry, vol. 280, no. 24, pp. 22721–22731, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. R. Zhao and I. D. Goldman, “Resistance to antifolates,” Oncogene, vol. 22, no. 47, pp. 7431–7457, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. R. C. Jackson, D. W. Fry, T. J. Boritzki et al., “Biochemical pharmacology of the lipophilic antifolate, trimetrexate,” Advances in Enzyme Regulation, vol. 22, pp. 187–206, 1984. View at Google Scholar · View at Scopus
  12. R. Yang, R. Sowers, B. Mazza et al., “Sequence alterations in the reduced folate carrier are observed in osteosarcoma tumor samples,” Clinical Cancer Research, vol. 9, no. 2, pp. 837–844, 2003. View at Google Scholar · View at Scopus
  13. W. Guo, J. H. Healey, P. A. Meyers et al., “Mechanisms of methotrexate resistance in osteosarcoma,” Clinical Cancer Research, vol. 5, no. 3, pp. 621–627, 1999. View at Google Scholar · View at Scopus
  14. T. Trippett, S. Schlemmer, Y. Elisseyeff et al., “Defective transport as a mechanism of acquired resistance to methotrexate in patients with acute lymphocytic leukemia,” Blood, vol. 80, no. 5, pp. 1158–1162, 1992. View at Google Scholar · View at Scopus
  15. R. G. Gorlick, D. H. Abramson, R. Sowers, B. A. Mazza, and I. J. Dunkel, “Impairments in antifolate transport are common in retinoblastoma tumor samples,” Pediatric Blood and Cancer, vol. 50, no. 3, pp. 573–576, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. P. A. Meyers, G. Heller, J. Healey et al., “Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan- Kettering experience,” Journal of Clinical Oncology, vol. 10, no. 1, pp. 5–15, 1992. View at Google Scholar · View at Scopus
  17. K. Winkler, G. Beron, G. Delling et al., “Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response,” Journal of Clinical Oncology, vol. 6, no. 2, pp. 329–337, 1988. View at Google Scholar · View at Scopus
  18. P. A. Meyers, E. Casper, A. Huvos et al., “Osteogenic sarcoma (OS): randomized trial of intensive preoperative (pre-op) chemo vs chemo guided by histologic response (hr) to pre-op chemo,” SIOP Meeting, vol. 28, p. 263, 1996, abstract. View at Google Scholar
  19. P. A. Meyers, G. Heller, J. H. Healey et al., “Osteogenic sarcoma with clinically detectable metastasis at initial presentation,” Journal of Clinical Oncology, vol. 11, no. 3, pp. 449–453, 1993. View at Google Scholar · View at Scopus
  20. R. Gorlick, E. Goker, T. Trippett et al., “Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression,” Blood, vol. 89, no. 3, pp. 1013–1018, 1997. View at Google Scholar · View at Scopus
  21. W. F. Flintoff, H. Sadlish, R. Gorlick, R. Yang, and F. M. R. Williams, “Functional analysis of altered reduced folate carrier sequence changes identified in osteosarcomas,” Biochimica et Biophysica Acta, vol. 1690, no. 2, pp. 110–117, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. Z. Hou, J. Wu, J. Ye, C. Cherian, and L. H. Matherly, “Substrate-specific binding and conformational changes involving Ser313 and transmembrane domain 8 of the human reduced folate carrier, as determined by site-directed mutagenesis and protein cross-linking,” Biochemical Journal, vol. 430, no. 2, pp. 265–274, 2010. View at Publisher · View at Google Scholar
  23. R. Yang, J. Qin, B. H. Hoang, J. H. Healey, and R. Gorlick, “Polymorphisms and methylation of the reduced folate carrier in osteosarcoma,” Clinical Orthopaedics and Related Research, vol. 466, no. 9, pp. 2046–2051, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. L. H. Matherly, Z. Hou, and Y. Deng, “Human reduced folate carrier: translation of basic biology to cancer etiology and therapy,” Cancer and Metastasis Reviews, vol. 26, no. 1, pp. 111–128, 2007. View at Publisher · View at Google Scholar · View at Scopus